Salbutamol + Ipratropium (Solution for inhalation) interactions
Checked as Salbutamol + Ipratropium in this data source.
Full monograph for Salbutamol + Ipratropium (Solution for inhalation)Check it against another medicine
Medicines
762 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Bimatoprost + Timololvia Salbutamol | Major | Antagonism · Unknown | Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or…2 documented mechanisms | 40 sources — open the full entry |
| Brimonidine Tartrate + Timolol Maleatevia Salbutamol | Major | Antagonism · Unknown | Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or…2 documented mechanisms | 40 sources — open the full entry |
| Brinzolamide + Timololvia Salbutamol | Major | Antagonism · Unknown | Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or…2 documented mechanisms | 40 sources — open the full entry |
| Carvedilolvia Salbutamol | Major | Antagonism | Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or… | 40 sources — open the full entry |
| Dorzolamide + Timololvia Salbutamol | Major | Antagonism | Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or… | 40 sources — open the full entry |
| Labetalol Hydrochloridevia Salbutamol | Major | Antagonism | Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or… | 40 sources — open the full entry |
| Latanoprost + Timololvia Salbutamol | Major | Antagonism · Unknown | Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or…2 documented mechanisms | 40 sources — open the full entry |
| Mifepristonevia Salbutamol | Major | Synergy | Mifepristone may prolong the QTc interval in a dose-related manner. Theoretically, coadministration with other agents that can prolong the QT interval may… | 10 sources — open the full entry |
| Mifepristone + Misoprostolvia Salbutamol | Major | Synergy · Unknown | Mifepristone may prolong the QTc interval in a dose-related manner. Theoretically, coadministration with other agents that can prolong the QT interval may…2 documented mechanisms | 10 sources — open the full entry |
| Propranolol Hydrochloridevia Salbutamol | Major | Antagonism | Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or… | 40 sources — open the full entry |
| Ribociclibvia Salbutamol | Major | Synergy | Ribociclib can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 16 sources — open the full entry |
| Sotalol Hydrochloridevia Salbutamol | Major | Antagonism | Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or… | 40 sources — open the full entry |
| Timolol Maleatevia Salbutamol | Major | Antagonism | Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or… | 40 sources — open the full entry |
| Travoprost + Timolol Maleatevia Salbutamol | Major | Antagonism · Unknown | Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or…2 documented mechanisms | 40 sources — open the full entry |
| Abiraterone Acetatevia Salbutamol | Moderate | Synergy | Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that… | 30 sources — open the full entry |
| Acarbosevia Salbutamol | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Acetazolamidevia Salbutamol | Moderate | Synergy | Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically… | 8 sources — open the full entry |
| Aclidinium Bromide + Formoterol Fumaratevia Salbutamol, Ipratropium | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists…2 documented mechanisms | 23 sources — open the full entry |
| Adenosinevia Salbutamol | Moderate | Synergy | Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents… | 18 sources — open the full entry |
| Adenosine + Cytochrome-C + Sodium Succinate + Nicotinamidevia Salbutamol | Moderate | Synergy | Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents… | 18 sources — open the full entry |
| Adrenalinevia Salbutamol | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Alfuzosin Hydrochloridevia Salbutamol | Moderate | Synergy | Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that… | 30 sources — open the full entry |
| Alogliptin Benzoatevia Salbutamol | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxidevia Salbutamol | Moderate | Synergy | Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in… | 6 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide + Simethiconevia Salbutamol | Moderate | Synergy | Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in… | 6 sources — open the full entry |
| Aminophyllinevia Salbutamol | Moderate | Synergy | Concomitant use of beta-2 adrenergic agonists with theophylline may increase the risk and/or severity of hypokalemia and adverse cardiovascular effects such as… | 26 sources — open the full entry |
| Amiodarone Hydrochloridevia Salbutamol | Moderate | Synergy | Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that… | 30 sources — open the full entry |
| Amisulpridevia Salbutamol | Moderate | Synergy | Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that… | 30 sources — open the full entry |
| Amitriptyline Hydrochloridevia Salbutamol, Ipratropium | Moderate | Synergy | Concomitant use of beta-2 adrenergic agonists with tricyclic antidepressants (TCAs) may increase the risk and/or severity of cardiovascular adverse effects…2 documented mechanisms | 23 sources — open the full entry |
| Amitriptyline Hydrochloride + Chlordiazepoxidevia Salbutamol, Ipratropium | Moderate | Synergy | Concomitant use of beta-2 adrenergic agonists with tricyclic antidepressants (TCAs) may increase the risk and/or severity of cardiovascular adverse effects…2 documented mechanisms | 23 sources — open the full entry |
| Amlodipine Besilate + Atenololvia Salbutamol | Moderate | Others · Unknown | Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in…2 documented mechanisms | 26 sources — open the full entry |
| Antazoline + Tetryzolinevia Salbutamol | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Apalutamidevia Salbutamol | Moderate | Synergy | Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that… | 30 sources — open the full entry |
| Arformoterol Tartratevia Salbutamol | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Aripiprazolevia Salbutamol, Ipratropium | Moderate | Others · Synergy | It is uncertain whether aripiprazole causes clinically significant prolongation of the QT interval.2 documented mechanisms | 32 sources — open the full entry |
| Armodafinilvia Salbutamol | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Arsenic Trioxidevia Salbutamol | Moderate | Synergy | Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that… | 30 sources — open the full entry |
| Artemether + Lumefantrinevia Salbutamol | Moderate | Synergy | Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that…2 documented mechanisms | 57 sources — open the full entry |
| Articaine Hydrochloride + Epinephrine Bitartratevia Salbutamol | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Asciminibvia Salbutamol | Moderate | Others | It is uncertain whether asciminib causes clinically significant prolongation of the QT interval of the electrocardiogram. | 2 sources — open the full entry |
| Asenapine Maleatevia Salbutamol | Moderate | Synergy | Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that… | 30 sources — open the full entry |
| Atenololvia Salbutamol | Moderate | Others | Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in… | 26 sources — open the full entry |
| Atenolol + Chlorthalidonevia Salbutamol | Moderate | Others · Synergy | Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in…2 documented mechanisms | 34 sources — open the full entry |
| Atomoxetine Hydrochloridevia Salbutamol | Moderate | Synergy | Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic… | 10 sources — open the full entry |
| Atropine Sulfate (Injection)via Salbutamol, Ipratropium | Moderate | Synergy · Unknown | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary…2 documented mechanisms | 12 sources — open the full entry |
| Azilsartan Medoxomil + Chlorthalidonevia Salbutamol | Moderate | Synergy | Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically… | 8 sources — open the full entry |
| Azithromycin DihydratebaseOphthalmicvia Salbutamol | Moderate | Synergy | Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that… | 30 sources — open the full entry |
| Beclometasone + Formoterol + Glycopyrroniumvia Salbutamol, Ipratropium | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists…3 documented mechanisms | 27 sources — open the full entry |
| Beclomethasone Dipropionate + Formoterol Fumaratevia Salbutamol | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists…2 documented mechanisms | 15 sources — open the full entry |
| Betamethasone + Phenylephrine + Lignocainevia Salbutamol | Moderate | Synergy · Unknown | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists…3 documented mechanisms | 15 sources — open the full entry |
Conditions
Conditions in which Salbutamol + Ipratropium (Solution for inhalation) needs care, as documented in this source.
Anticholinergic Syndrome
ModerateAclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents. Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported. Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug. Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma. Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization. Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).
11 sources
- Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988): 486-94
- Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990): 123-5
- Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989): 260-1
- Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991): 939-40
- Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985): 5-12
- Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980): 237-66
- "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim (2002):
- "Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim
Show all 11 sourcesShow fewer sources
- "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim (2002):
- "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals (2012):
- "Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline (2014):
Cardiovascular Diseases
ModerateAdrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. However, beta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension. The recommended dosages should not be exceeded.
51 sources
- Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988): 385-7
- Larsson S "Long-term treatment with beta2-adrenostimulants in asthma. Side effects, selectivity, tolerance, and routes of administration." Acta Med Scand Suppl 608 (1977): 1-40
- Mettauer B, Rouleau JL, Burgess JH "Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure." Am Heart J 109 (1985): 840-7
- Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9
- Vathenen AS, Britton JR, Ebden P, Cookson JB, Wharrad HJ, Tattersfield AE "High-dose inhaled albuterol in severe chronic airflow limitation." Am Rev Respir Dis 138 (1988): 850-5
- Godfrey S "Worldwide experience with albuterol (salbutamol)." Ann Allergy 47 (1981): 423-6
- Finch JS "Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial." Ann Allergy 47 (1981): 402-4
- Neville E, Corris PA, Vivian J, Nariman S, Gibson GJ "Nebulised salbutamol and angina." Br Med J (Clin Res Ed) 285 (1982): 796-7
Show all 51 sourcesShow fewer sources
- Breeden CC, Safirstein BH "Albuterol and spacer-induced atrial fibrillation." Chest 98 (1990): 762-3
- Wolfe JD, Yamate M, Biedermann AA, Chu TJ "Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics." JAMA 253 (1985): 2068-72
- Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9
- Shovlin CL, Tam FW "Salbutamol nebuliser and precipitation of critical cardiac ischaemia." Lancet 336 (1990): 1258
- Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS "The use of beta-agonists and the risk of death and near death from asthma." N Engl J Med 326 (1992): 501-6
- Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989): 77-122
- Richards DM, Brogden RN "Pirbuterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible bronchospastic disease." Drugs 30 (1985): 6-21
- Lampert MB, Hibbard J, Weinert L, Briller J, Lindheimer M, Lang RM "Peripartum heart failure associated with prolonged tocolytic therapy." Am J Obstet Gynecol 168 (1993): 493-5
- Al-Hillawi AH, Hayward R, Johnson NM "Incidence of cardiac arrhythmias in patients taking slow release salbutamol and slow release terbutaline for asthma." Br Med J (Clin Res Ed) 288 (1984): 367
- Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32
- "Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology." J Allergy Clin Immunol 75 (1985): 443-9
- Wagner JM, Morton MJ, Johnson KA, O'Grady JP, Speroff L "Terbutaline and maternal cardiac function." JAMA 246 (1981): 2697-701
- Kinney EL, Trautlein JJ, Harbaugh CV, Lambert D, Zelis RF "Ventricular tachycardia after terbutaline." JAMA 240 (1978): 2247
- Whitsett TL, Manion CV, Wilson MF "Cardiac, pulmonary and neuromuscular effects of clenbuterol and terbutaline compared with placebo." Br J Clin Pharmacol 12 (1981): 195-200
- Brogden RN, Speight TM, Avery GS "Terbutaline: a preliminary report of its pharmacological properties and therapeutic efficacy in asthma." Drugs 6 (1973): 324-32
- Trautlein J, Allegra J, Gillin M "Aerosolized terbutaline sulfate--an evalution of efficacy and side effects in patients with reversible airway disease." J Clin Pharmacol 17 (1977): 76-80
- Maguire GP, Emirgil C "Bronchodilator and side effects of different modes of administration of metaproterenol: inhaled, oral, and in combination." Am J Med Sci 291 (1986): 168-74
- Ence TJ, Tashkin DP, Ho D, Child JS "Acute bronchial and cardiovascular effects of oral pirbuterol and metaproterenol." Ann Allergy 43 (1979): 229-36
- Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9
- "Product Information. Proventil (albuterol)." Schering Corporation (2002):
- "Product Information. Ventolin (albuterol)." Glaxo Wellcome (2002):
- "Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals (2001):
- Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993): 1478-87
- Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992): 342-5
- Brogden RN, Faulds D "Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease." Drugs 42 (1991): 895-912
- Littner MR, Tashkin DP, Calvarese B, Bautista M "Acute bronchial and cardiovascular effects of increasing doses of pirbuterol acetate aerosol in asthma." Ann Allergy 48 (1982): 14-20
- Chodosh S, Crooks LA, Tuck J "Comparative effects of pirbuterol acetate, metaproterenol, and placebo aerosols on pulmonary function and incidence of cardiac ectopy." J Asthma 26 (1989): 309-15
- "Product Information. Serevent (salmeterol)." Glaxo Wellcome
- "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals (2001):
- "Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim (2001):
- Hibbard JU "Chronic terbutaline therapy and peripartum cardiomyopathy: a case-control study." Hypertens Pregnancy 15 (1996): 183-91
- Katz M, Robertson PA, Creasy RK "Cardiovascular complications associated with terbutaline treatment for preterm labor." Am J Obstet Gynecol 139 (1981): 605-8
- Suissa S, Hemmelgarn B, Blais L, Ernst P "Bronchodilators and acute cardiac death." Am J Respir Crit Care Med 154 (1996): 1598-602
- Tranfa CME, Pelaia G, Grembiale RD, Naty S, Durante S, Borrello G "Short-term cardiovascular effects of salmeterol." Chest 113 (1998): 1272-6
- Braden GL, Germain MJ, Mulhern JG, Hafer JG, Bria WF "Hemodynamic, cardiac, and electrolyte effects of low-dose aerosolized terbutaline sulfate in asthmatic patients." Chest 114 (1998): 380-7
- Jenne JW "Can oral beta(2) agonists cause heart failure?" Lancet 352 (1998): 1081-2
- "Product Information. Tornalate (bitolterol)." Apothecon Inc (2022):
- Nathan RA, Bronsky EA, Dockhorn RJ, Kemp JP "Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma." Ann Allergy 72 (1994): 209-16
- Bierman CW, Kemp JP, Nathan RA "Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma." Ann Allergy Asthma Immunol 76 (1996): 27-35
- Pinnas JL, Bhatt BD, Campbell SC, Kemp JP, Tinkelman DG "Dose-response study of nebulized bitolterol mesylate solution in asthmatic patients." Chest 91 (1987): 533-9
- "Product Information. Xopenex (levalbuterol)." Sepracor Inc (2001):
- Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999): 615-21
- "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim (2014):
Diabetes Mellitus
ModerateAdrenergic bronchodilators may cause increases in blood glucose concentrations. These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended. Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis. Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate. Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.
17 sources
- Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988): 385-7
- Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9
- Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989): 77-122
- Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32
- "Product Information. Proventil (albuterol)." Schering Corporation (2002):
- "Product Information. Ventolin (albuterol)." Glaxo Wellcome (2002):
- "Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals (2001):
- Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993): 1478-87
Show all 17 sourcesShow fewer sources
- Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992): 342-5
- "Product Information. Serevent (salmeterol)." Glaxo Wellcome
- "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals (2001):
- "Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim (2001):
- "Product Information. Tornalate (bitolterol)." Apothecon Inc (2022):
- "Product Information. Xopenex (levalbuterol)." Sepracor Inc (2001):
- Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999): 615-21
- "Product Information. Foradil (formoterol)." Novartis Pharmaceuticals (2001):
- "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim (2014):
Hypokalemia
ModerateAdrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration. Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects. The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown. Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.
30 sources
- Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71
- Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9
- Allon M, Dunlay R, Copkney C "Nebulized albuterol for acute hyperkalemia in patients on hemodialysis." Ann Intern Med 110 (1989): 426-9
- Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9
- "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1
- Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20
- Montoliu J, Almirall J, Ponz E, Campistol JM, Revert L "Treatment of hyperkalaemia in renal failure with salbutamol inhalation." J Intern Med 228 (1990): 35-7
- Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9
Show all 30 sourcesShow fewer sources
- Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989): 77-122
- Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6
- Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5
- Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32
- Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6
- Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9
- "Product Information. Proventil (albuterol)." Schering Corporation (2002):
- "Product Information. Ventolin (albuterol)." Glaxo Wellcome (2002):
- "Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals (2001):
- Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993): 1478-87
- Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992): 342-5
- Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61
- "Product Information. Serevent (salmeterol)." Glaxo Wellcome
- "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals (2001):
- Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9
- "Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim (2001):
- Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75
- Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7
- "Product Information. Tornalate (bitolterol)." Apothecon Inc (2022):
- "Product Information. Xopenex (levalbuterol)." Sepracor Inc (2001):
- Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999): 615-21
- "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim (2014):
Kidney Diseases
ModerateLevalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.
1 source
- "Product Information. Xopenex (levalbuterol)." Sepracor Inc (2001):
Liver Failure
ModerateIpratropium has not been studied in patients with hepatic or renal insufficiency. Therapy with this agent should be used with caution in these patients.
1 source
- "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim (2002):
Seizures
ModerateAdrenergic bronchodilators may cause CNS stimulation. Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders. Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.
12 sources
- Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9
- Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989): 77-122
- "Product Information. Proventil (albuterol)." Schering Corporation (2002):
- "Product Information. Ventolin (albuterol)." Glaxo Wellcome (2002):
- "Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals (2001):
- "Product Information. Serevent (salmeterol)." Glaxo Wellcome
- "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals (2001):
- "Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim (2001):
Show all 12 sourcesShow fewer sources
- "Product Information. Tornalate (bitolterol)." Apothecon Inc (2022):
- "Product Information. Xopenex (levalbuterol)." Sepracor Inc (2001):
- "Product Information. Foradil (formoterol)." Novartis Pharmaceuticals (2001):
- "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim (2014):
Tachycardia
ModerateCases of supraventricular tachycardia and atrial fibrillation have been reported with the use of inhaled anticholinergic agents in patients with COPD/Asthma. Care and monitoring of cardiac function is recommended when prescribing these agents to patients at risk.
2 sources
- "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim (2002):
- "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim (2002):
Therapeutic duplication
Drug classes that overlap with Salbutamol + Ipratropium (Solution for inhalation), so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Olodaterol/tiotropium
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Chlorpheniramine/methscopolamine/phenylephrine
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Urolet mb
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Phosphasal
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Glycopyrrolate/indacaterol
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Sympak ii
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Motofen
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Librax
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Trelegy ellipta
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Butabarbital/hyoscyamine/phenazopyridine
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): B & o supprettes
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Hyoscyamine/phenyltoloxamine
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Duaklir pressair
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Duodote
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Tussigon
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Budesonide/formoterol/glycopyrrolate
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Vi-atro
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Anoro ellipta
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Glycopyrrolate/neostigmine
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Prosed ds
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Formoterol/glycopyrrolate
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Phenohytro
inhaled smooth muscle relaxants
The recommended maximum number of medicines in the 'inhaled smooth muscle relaxants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'inhaled smooth muscle relaxants' category.
Example product in the source data (US market): Formoterol/mometasone
inhaled smooth muscle relaxants
The recommended maximum number of medicines in the 'inhaled smooth muscle relaxants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'inhaled smooth muscle relaxants' category.
Example product in the source data (US market): Glycopyrrolate/indacaterol
inhaled smooth muscle relaxants
The recommended maximum number of medicines in the 'inhaled smooth muscle relaxants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'inhaled smooth muscle relaxants' category.
Example product in the source data (US market): Epinephrine/prilocaine
inhaled smooth muscle relaxants
The recommended maximum number of medicines in the 'inhaled smooth muscle relaxants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'inhaled smooth muscle relaxants' category.
Example product in the source data (US market): Trelegy ellipta
inhaled smooth muscle relaxants
The recommended maximum number of medicines in the 'inhaled smooth muscle relaxants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'inhaled smooth muscle relaxants' category.
Example product in the source data (US market): Orabloc
inhaled smooth muscle relaxants
The recommended maximum number of medicines in the 'inhaled smooth muscle relaxants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'inhaled smooth muscle relaxants' category.
Example product in the source data (US market): Fluticasone/vilanterol
inhaled smooth muscle relaxants
The recommended maximum number of medicines in the 'inhaled smooth muscle relaxants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'inhaled smooth muscle relaxants' category.
Example product in the source data (US market): Symbicort
inhaled smooth muscle relaxants
The recommended maximum number of medicines in the 'inhaled smooth muscle relaxants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'inhaled smooth muscle relaxants' category.
Example product in the source data (US market): Vivacaine
inhaled smooth muscle relaxants
The recommended maximum number of medicines in the 'inhaled smooth muscle relaxants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'inhaled smooth muscle relaxants' category.
Example product in the source data (US market): Duaklir pressair
inhaled smooth muscle relaxants
The recommended maximum number of medicines in the 'inhaled smooth muscle relaxants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'inhaled smooth muscle relaxants' category.
Example product in the source data (US market): Budesonide/formoterol/glycopyrrolate
inhaled smooth muscle relaxants
The recommended maximum number of medicines in the 'inhaled smooth muscle relaxants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'inhaled smooth muscle relaxants' category.
Example product in the source data (US market): Anoro ellipta
inhaled smooth muscle relaxants
The recommended maximum number of medicines in the 'inhaled smooth muscle relaxants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'inhaled smooth muscle relaxants' category.
Example product in the source data (US market): Epinephrine/lidocaine
inhaled smooth muscle relaxants
The recommended maximum number of medicines in the 'inhaled smooth muscle relaxants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'inhaled smooth muscle relaxants' category.
Example product in the source data (US market): Formoterol/glycopyrrolate
inhaled smooth muscle relaxants
The recommended maximum number of medicines in the 'inhaled smooth muscle relaxants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'inhaled smooth muscle relaxants' category.
Example product in the source data (US market): Olodaterol/tiotropium
inhaled smooth muscle relaxants
The recommended maximum number of medicines in the 'inhaled smooth muscle relaxants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'inhaled smooth muscle relaxants' category.
Example product in the source data (US market): Wixela inhub